ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle-Invasive Bladder Cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 32 citations in OpenAlex.
- An integrated molecular classification system identifies distinct prognostic clusters of non-muscle-invasive bladder cancer.Functional & integrative genomics · 2026Article
- Pan-Cancer Targeted Sequencing Reveals Genomic Heterogeneity and Prognostic Subgroups in Urothelial Bladder Cancer.Cancers · 2026Article
- STAG2 expression imparts distinct therapeutic vulnerabilities in muscle-invasive bladder cancer cells.Oncogenesis · 2025Article
- Molecular biomarkers of progression in non-muscle-invasive bladder cancer - beyond conventional risk stratification.Nature reviews. Urology · 2025Review
- STAG2 regulates polycomb and differentiation in urothelial precursors and bladder cancer.PloS one · 2025Article
- Circular STAG2 RNA Modulates Bladder Cancer Progression via miR-145-5p/TAGLN2 and Is Considered as a Biomarker for Recurrence.Cancers · 2024Article
- Article
- FLI1 and FRA1 transcription factors drive the transcriptional regulatory networks characterizing muscle invasive bladder cancer.Communications biology · 2023Article
- Identification ofFrontiers in oncology · 2023Article
- Identification of STAG2-Mutant Bladder Cancers by Immunohistochemistry.Methods in molecular biology (Clifton, N.J.) · 2023Article
- A study of the immunohistochemical profile of bladder cancer in neuro-urological patients by the French Association of Urology.World journal of urology · 2022Article
- Bladder carcinomas in patients with neurogenic bladder and urinary schistosomiasis: are they the same tumors?World journal of urology · 2022Article
- STAG2 Protein Expression in Non-muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes.European urology open science · 2022Article
- Non-muscle invasive bladder cancer biomarkers beyond morphology.Frontiers in oncology · 2022Review
- STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer.Urologic oncology · 2021Article
- A four-antibody immunohistochemical panel can distinguish clinico-pathological clusters of urothelial carcinoma and reveals high concordance between primary tumor and lymph node metastases.Virchows Archiv : an international journal of pathology · 2021Article
- The Regulatory Role of RNA Metabolism Regulator TDP-43 in Human Cancer.Frontiers in oncology · 2021Review
- Emerging themes in cohesin cancer biology.Nature reviews. Cancer · 2020Review
- Identification of a 13‑mRNA signature for predicting disease progression and prognosis in patients with bladder cancer.Oncology reports · 2020Article
- Advances in urinary biomarker discovery in urological research.Investigative and clinical urology · 2020Review
Corrections and comments
- Commented on by
Authors and funding
15 authors at 2 institutions in 2 countries.
Alana LeloDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, District of Columbia.
Frederik PripDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Brent T HarrisDepartment of Pathology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, District of Columbia.
David SolomonDepartment of Pathology, University of California San Francisco School of Medicine, San Francisco, California.
Deborah L BerryDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, District of Columbia.
Krysta ChaldekasHistopathology and Tissue Shared Resource, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, District of Columbia.
Anagha KumarDepartment of Biostatistics, MedStar Health Research Institute, Washington, District of Columbia.
Jeffry SimkoDepartment of Pathology, University of California San Francisco School of Medicine, San Francisco, California.
Jørgen Bjerggaard JensenDepartment of Urology, Aarhus University Hospital, Aarhus, Denmark.
Pritish BhattacharyyaDepartment of Pathology, Hackensack University Medical Center, Hackensack, New Jersey.
Ciaran MannionDepartment of Pathology, Hackensack University Medical Center, Hackensack, New Jersey.
Jung-Sik KimDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, District of Columbia.
George PhilipsDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, District of Columbia.
Lars DyrskjøtDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Todd WaldmanDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, District of Columbia. waldmant@georgetown.edu.
Aarhus University Hospital · DKGeorgetown University · US
Funding
Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI KAREN A CRESWELL · 1990 to 2026
$71.5MMaternal Morbidity and Mortality: Risk Factors, Early Detection and Personalized InterventionUL1TR001409 · NCATS · GEORGETOWN UNIVERSITY · PI GONDRE-LEWIS, MARJORIE C, MELLMAN, THOMAS A · 2015 to 2024
$37.8MTRAINING GRANT IN TUMOR BIOLOGYT32CA009686 · NCI · GEORGETOWN UNIVERSITY · PI ANNA Tate RIEGEL, DAVID J ROBBINS · 1996 to 2026
$10.8MTranslational Biomedical Science Training GrantTL1TR001431 · NCATS · GEORGETOWN UNIVERSITY · PI LEE, DEXTER L, SANDBERG, KATHRYN L · 2015 to 2024
$4.8MCohesin gene mutations in tumorigenesisDP5OD021403 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SOLOMON, DAVID A. · 2015 to 2019
$2.0MAnalysis of STAG2 Inactivation and Aneuploidy in Human CancerR01CA169345 · NCI · GEORGETOWN UNIVERSITY · PI WALDMAN, TODD A · 2013 to 2017
$1.6MNCATS NIH HHS TL1 TR001431NCATS NIH HHS UL1 TR001409NCI NIH HHS P30 CA051008NCI NIH HHS R01 CA169345NCI NIH HHS T32 CA009686NIH HHS DP5 OD021403
Abstract
PubMed holds no abstract for this paper.
Indexed as
AgedAntigens, NuclearCell Cycle ProteinsCohesinsDisease-Free SurvivalDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedMusclesNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingUrinary Bladder NeoplasmsAntigens, NuclearCell Cycle ProteinsCohesinsSTAG2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.